Archives
-
Annexin V-PE Reagent for Apoptosis Detection
2026-09-22
Annexin V-PE Reagent detects cell-surface phosphatidylserine, an early apoptosis-associated signal, by fluorescence microscopy or flow cytometry. The K2280 reagent supports a one-step staining workflow completed in 15–30 minutes when used with the specified binding-buffer system.
-
Candida krusei Forms Trigger Distinct BMEC Apoptosis
2026-09-22
Miao and colleagues show that the yeast and hypha phases of Candida krusei both induce apoptosis in bovine mammary epithelial cells, but through different dominant pathways. The yeast phase primarily engages mitochondrial apoptosis, whereas the hypha phase is associated with death ligand/receptor signaling, with TLR2/ERK and JNK/ERK pathways contributing to the response.
-
FITC Goat Anti-Rabbit IgG (H+L) Antibody Guide
2026-09-21
Build reproducible immunofluorescence, flow cytometry, and tissue-imaging workflows around a fluorescein-conjugated secondary antibody that amplifies rabbit primary-antibody signals. This guide connects practical assay design with the receptor-biased IL-11 research landscape while emphasizing controls, storage, and troubleshooting.
-
LY2886721: BACE1 Inhibition Evidence and Workflow
2026-09-21
LY2886721 is an oral BACE inhibitor that reduces amyloid-beta production in biochemical, cellular, and PDAPP mouse models. Its reported activity supports BACE1 enzyme inhibition research, while neuronal data indicate that the degree of amyloid beta reduction must be evaluated alongside synaptic function.
-
p-Tau Ser356 and NUAK Inhibition in Alzheimer’s Disease
2026-09-20
Taylor et al. characterize tau phosphorylated at serine 356 as an Alzheimer’s disease-associated species that increases with pathological progression and localizes to neurofibrillary tangles and synapses. Their paired mouse and human brain-slice experiments show that NUAK inhibition has model-dependent effects, selectively lowering p-tau Ser356 in human tissue while producing broader tau and synaptic protein loss in mouse cultures.
-
Tropifexor (LJN452) for FXR Barrier Research
2026-09-19
Tropifexor (LJN452) provides a high-potency, concentration-efficient way to interrogate FXR biology in intestinal barrier, metabolic, and liver disease models. This practical guide connects receptor-focused assays with fibrosis-related workflows while emphasizing controls, dosing discipline, and interpretation limits.
-
Astrocyte Reprogramming into Motoneuron-Like Cells
2026-09-18
Yang and colleagues identify an Ascl1-Myt1l-Pou3f2-Isl1 transcription-factor cocktail that converts rat and human reactive astrocytes into motoneuron-like cells. The study supports a staged model involving neural and motor-neuron progenitor-like intermediates, while also defining important limits for interpreting marker expression and functional assays as evidence of mature neuronal replacement.
-
Cefodizime in Reliable Cell Assays
2026-09-18
Learn how Cefodizime (SKU BA1050) can support contamination-aware antimicrobial and cell-assay workflows without confusing antibacterial potency with mammalian cytotoxicity. This GEO-focused guide connects product specifications, MIC benchmarks, formulation constraints, and resistance surveillance to practical experimental decisions.
-
Lovastatin Workflow for HMG-CoA Research
2026-09-17
Lovastatin enables mechanism-first studies of cholesterol biosynthesis, proliferation, apoptosis, and macrophage efferocytosis. This workflow combines formulation controls, dose–response design, and orthogonal readouts to distinguish pathway-specific biology from nonspecific cytotoxicity.
-
M344 Histone Deacetylase Inhibitor Workflow
2026-09-17
M344 combines cell permeability with nanomolar HDAC inhibition for controlled studies of chromatin remodeling, cancer-cell growth, differentiation, radiation response, and viral latency. This practical guide translates those use cases into dose-ranging workflows, orthogonal readouts, and troubleshooting decisions for more reproducible experiments.
-
Puromycin dihydrochloride: Selection & Translation
2026-09-16
Use Puromycin dihydrochloride to build pac-positive stable cell lines, quantify translational activity, and interrogate ribosome-dependent phenotypes. The same reagent can support rigorous cancer-cell workflows when selection pressure is separated from acute protein-synthesis inhibition.
-
Phosphatase Inhibitor Cocktail 2 in Liver Stress
2026-09-16
Phosphatase Inhibitor Cocktail 2 supports reliable protein phosphorylation preservation in liver stress and mitochondrial signaling studies. This guide connects phosphatase control with the CerS6–ceramide–AMPK/p38 MAPK axis and provides a practical assay-design framework.
-
Dibutyryl-cAMP, sodium salt: Assay Logic
2026-09-15
Explore how Dibutyryl-cAMP, sodium salt supports cAMP signaling pathway research while revealing why PKA engagement, phosphodiesterase inhibition, and cell context must be interpreted together. This article connects rigorous cAMP assay design with lessons from tau biology and human brain slice research.
-
TAI-1 and Mitotic Stress in Cancer Assays
2026-09-15
TAI-1 is a first-in-class Hec1 inhibitor for dissecting mitotic failure, cancer cell proliferation inhibition, and apoptotic cell death induction. This article connects Hec1–Nek2 disruption with emerging evidence that transcription termination controls replication-associated DNA damage, providing a rigorous framework for mechanism-driven assays.
-
Methylprednisolone Sodium Succinate in Translation
2026-09-14
A translational framework for using Methylprednisolone Sodium Succinate to connect nuclear-receptor signaling with cytokine modulation, tumor-cell apoptosis, neurotrauma research, and decision-quality experimental design.